Curated News
By: NewsRamp Editorial Staff
April 29, 2025
Gedeptin's Potential in Solid Tumors: New Clinical Data Presented at AACR
TLDR
- Gedeptin presents promising data for solid tumors, offering potential competitive advantage in cancer treatment.
- Gedeptin uses viral-vectored gene therapy with intratumoral and intravenous administration, targeting quiescent tumor cells for selective cytotoxicity.
- Gedeptin's clinical results show efficacy in advanced cancers, paving the way for novel tumor-targeted therapies to improve patient outcomes.
- GeoVax's Gedeptin therapy at AACR unveils innovative gene-directed prodrug approach, revolutionizing cancer treatment strategies.
Impact - Why it Matters
This news highlights the progress in gene-directed prodrug therapy for solid tumors, offering hope for patients with advanced and refractory cancers. The promising results from the study and upcoming Phase 2 trial demonstrate the potential of Gedeptin in improving treatment outcomes and leveraging immunotherapy against difficult-to-treat cancers.
Summary
GeoVax Labs, Inc. presented new clinical data on its gene-directed enzyme prodrug therapy, Gedeptin®, at the AACR Annual Meeting 2025. The study evaluated the safety and efficacy of Gedeptin in patients with advanced head and neck cancer, showing promising results with stable disease and minimal adverse events.
Following the positive outcomes, GeoVax plans to conduct a Phase 2 combination therapy trial with pembrolizumab for relapsed squamous cell head and neck cancer. Gedeptin's mechanism of action offers a targeted approach for treating solid tumors, potentially enhancing the clinical response.
Source Statement
This curated news summary relied on this press release disributed by NewMediaWire. Read the source press release here, Gedeptin's Potential in Solid Tumors: New Clinical Data Presented at AACR
